Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil tentatively approved for the treatment of pulmonary arterial... More drugs in developmentDrug Information A to Z Drug List Treatment Options Drugs by Class Dosage Side Effects Medical Q & A Generic Drugs Harvard...
Drug Information A to Z Drug List Treatment Options Drugs by Class Dosage Side Effects Medical Q & A Generic Drugs Harvard Health Guide Phonetic Search Pregnancy Warnings OTC Database Inactive Ingredients Veterinary Drugs International Drugs Info en Español Pricing & Coupon Guide...
Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil tentatively approved for the treatment of pulmonary arterial... More drugs in developmentDrug Information A to Z Drug List Treatment Options Drugs by Class Dosage Side Effects Medical Q & A Generic Drugs Harvard...
FDA Approves Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain (BUSINESS WIRE)--Jan. 30, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration... 4 days ago New Drug Approvals FD...
Drug class:Selective serotonin reuptake inhibitors Medically reviewed byKaci Durbin, MD. Last updated on Nov 28, 2024. Uses Warnings Before taking Dosage Side effects Interactions FAQ What is fluoxetine? Fluoxetineis aselective serotonin reuptake inhibitor(SSRI) antidepressant. Fluoxetine inhibits the upta...
Drug class:Antimanic agents Medically reviewed byPhilip Thornton, DipPharm. Last updated on Aug 14, 2023. Uses Warnings Before taking Dosage Side effects Interactions FAQ What is lithium? Lithiumaffects the flow of sodium through nerve and muscle cells in the body. Sodium affects excitation or ma...
Kooijmans SA, Vader P, van Dommelen SM, et al. Exosome mimetics: a novel class of drug delivery systems. Int J Nanomed. 2012;7:1525–41. CASGoogle Scholar Lai RC, Yeo RW, Tan KH, Lim SK. Exosomes for drug delivery: a novel application for the mesenchymal stem cell. Biotechnol Adv...
First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT...